A double-blind, comparative and prospective study with nifedipine once a day was undertaken, in patients with mild and moderate high blood pressure. Blood pressure was measured by mercury sphygmomanometer in two positions: resting and sitting at 3, 6 and 12 weeks of treatment and by ambulatory blood pressure monitoring (ABPM) over 24 h; both were carried out before and after the treatment and the uniformity in the pressure levels were obtained by means of the Smoothness Index. Fiftyfour patients were included in the trial, 28 in the microgranules group and 26 in the osmotic pump group. These groups were similar at the baseline in age, gender, weight, height, diastolic and systolic blood pressure. The nifedipine microgranules group had a heart rate higher than the nifedipine osmotic pump group at baseline (X M = 75.58 vs X B = 70.75). Blood pressure decreased significantly during the first 3 weeks; 85% in
Introduction
Calcium antagonists represent an alternative in the blood pressure (BP) treatment recommended as firstline drugs. 1 Among this type of drug, the dihydropyridine derivatives have been the most widely used. 2 Within this class, nifedipine has shown to be effective in controlling high blood pressure 3, 4 however its side effects due to its potency and short biological half-life have led to the introduction of a sustained release formulation, the nifedipine GITS (gastrointestinal therapeutic system) with a controlled and continuous release over 16-18 h, with plasmatic levels maintained for 24 h with a single daily dosage 5 in order to reduce BP equally and maintaining their therapeutic efficacy. 6 In Venezuela, another nifedipine formulation is available in the form of microgranules 7, 8 with a programmed
Correspondence: M González, Laboratorios Leti, S.A.V., Edif. Laboratorios Leti, Direcció n Médica, Zona Industrial del Este, Avenida 2, Guarenas, Miranda 1220, Venezuela the microgranules group and 75% in the osmotic pump group reached a blood pressure р140/90 mm Hg at the end of the study. Three patients in the microgranules group and two in the osmotic pump group required an additional antihypertensive drug. In both groups, the average blood pressure over 24 h was lowered without differences between groups. A decrease was induced in the heart rate in both groups which reached a marginal statistical significance in the microgranules nifedipine group. No changes were induced in the laboratory tests; two patients in the microgranules (8%) nifedipine group and five in the nifedipine osmotic pump group, adverse effects were observed, of which only one in each group required stopping the treatment. release and maintenance of constant plasmatic levels over 24 h with the administration of a single daily dosage, with a galenic different from that of the osmotic pump. Calcium antagonists cause their antihypertensive action by blocking the dependent voltage calcium L channels; they also have an antiatherogenic property, because the vascular smooth muscle has this type of calcium channel, they restore the endothelial function expressed as the endothelial response to the acetilcholine in patients with high BP treated with nifedipine, suggesting a reduction in the oxidative stress in the endothelium with an increase in the bioavailability of nitric oxide, 9 also in the INTAC study a decrease was reported in the number of new lesions and a lower progression of coronary artery injuries. 10 The GITS nifedipine or osmotic pump (NOP) and in nifedipine microgranules (NMG) have been shown to have a good sustained antihypertensive effect and good tolerance 6, 11, 12 in clinical studies. This study has been executed to assess the impact 
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Methods
Patients with essential moderate hypertension were selected, with a diastolic BP (DBP) between 90-115 mm Hg and systolic BP (SBP) Ͻ200 mm Hg, aged between 18 and 65 years of either sex, for a comparative study between NOP and NMG in a double-blind randomised and prospective design. During the initial selection, patients with the following diagnoses are excluded: serious concomitant diseases, pregnancy or lactation and known intolerance to nifedipine, subsequent to a routine clinical history, laboratory and medical examination.
Basal measurements were made after 2 weeks of placebo. At the end of that phase, patients with a DBP between 90 and 115 mm Hg (average of three measurements taken at 2-min intervals after an initial rest period of 5 min using a mercury sphygmomanometer, in a sitting position and with trained staff) were assigned at random to receive 30 mg of nifedipine supplied once a day in the form of NOP or NMG. A written consent has been obtained from patients after explaining the protocol which has been previously accepted by the ethics committee. BP measurements, heart rate (HR) and adverse effects reports were made after 3, 6, and 12 weeks of treatment. If by the third week a DBP Ͻ90 mm Hg and SBP Ͻ140 mm Hg had not been reached, the dose was increased to 60 mg per day; if by the sixth week, BP was not controlled, enalapril is added and these patients were withdrawn.
Before and after the treatment period, laboratory examinations and ABPM were measured using an Auto Cuff recorder, model 1001 (Biotrac) by oscillometric method. The patients were instructed to perform their usual activities and stop when BP was measured. The monitor was programmed to obtain measurements every 15 min between 07.00 and 23.00 h, and every 30 min during night time (23.00 to 07.00 h). MABP (outpatient non-invasive monitoring) reports SBP, DBP, HR and mean arterial pressure (MAP) over 24 h, day and night.
Statistical analysis
The Student's t-test is used for dependent samples and Wilcoxon range analyses to evaluate changes that occur between treatment phases for HR, SBP, DBP, both recorded by mercury sphygmomanometry or by ABPM. In both cases, 5% is determined for the significance level. To compare the two treatments, the t-test is used for independent samples and the non-parametric Mann-Whitney test.
Results
A total of 54 patients, 44 of the female gender and 10 of the male gender, participated and completed the study with an average age of 54 years. Four patients were excluded for having more than 10% of all readings lost or incorrect. They were allocated at random as follows:
• NMG group: 28 participants, received microgranules nifedipine, 12 weeks; • NOP group: 26 participants, received osmotic pump nifedipine, 12 weeks.
The demographic data
In the NMG group there were 22 of the female gender and six of the male gender, with an average age of 54.8 ± 8.9 years, weight of 53.8 ± 10.8 kg and height of 1.59 ± 0.07 cm. In the NOP group there were 22 of the female gender and four of the male gender, an average age of 53.8 years, weight of 69.3 ± 12 kg and a height of 1.56 ± 0.07. No significant differences were found between ages (P = 0.69887), weight (P = 0.94797), height (P = 0.18390) between study groups. (Table 1, Figures 1, 2 and 3): Table 1 shows the changes in SBP, DBP and HR in supine position, which were also performed in a sitting position in a similar way and with statistical significance.
Changes in BP and HR by mercury sphygmomanometer
SBP: NOP group: baseline value was 162.2 ± 16 mm Hg with a decrease of BP upon 12 weeks of −16 ± 10.4 mm Hg −10% P Ͻ 0.0001. NMG group: baseline value of 163.17 ± 14.2 with decrease of BP upon 12 weeks of 22 ± 11.78 mm Hg, −14% P = 0.0001. There were no significant differences of basal value between NOP and NMG groups, (P = 0.777), and after 12 weeks of treatment (P = 0.96). The decrease response in BP was observed after 3 weeks of treatment in both groups (P = 0.000).
DBP: NOP group: baseline value was of 97 ± 7.3 mm Hg after 12 weeks was reduced in −17 ± 5.95 mm Hg%, −18% P Ͻ 0.001. NMG group: baseline value 95.6 ± 5.7 mm Hg, with a decrease after 12 weeks of 15 ± 7.9 mm Hg, 16% P Ͻ 0.0001. There were no significant differences of the baseline value between groups (P = 0.585) and after 12 weeks (P = 0.26) between NOP and NMG. A significant decrease was observed in both groups after 3 weeks of treatment P Ͻ 0.0001. Eighty-five percent of the NMG group and 75% of the NOP group showed a BP below 140/90 mm Hg after 12 weeks of treatment.
HR: NOP group: baseline value was 70.6 ± 6.5 with significant increase after 12 weeks of +3 ppm P = 0.008, +5%. NMG group: basal value was 75.5 ± 7.5 S153 
Figure 3
Heart rate.
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with decrease after 12 weeks −3 ppm (P = 0.003), −5%.
Comparison of values between NOP and NMG groups in the baseline P = 0.005 was significant and final P = 0.2186 was not significant. Table 2 ): ABPM over 24 h, at the beginning both groups showed similar hour pressures. At the end of the treatment period, a significant decrease was observed from the placebo value in MAP of 24 h with both treatments, as well as MAP during day and night without differences between the two drugs ( Table 2) .
Changes in median BP by ABPM (Figures 4 and 5,
Side effects and tolerance
Both formulations were well tolerated; two patients in the NMG group presented ankle oedema and five patients of the NOP group showed side effects (two with oedema, one with headache and tachycardia, two with facial flushing). The drug was not stopped in any of the cases during the treatment period.
Discussion
Our results suggest that nifedipine in microgranules and the osmotic pump type, used as monotherapy once a day for 12 weeks in the treatment of patients with high blood pressure from mild to moderate, induce a prompt and similar decrease in BP, 75% under treatment with NOP, and 85% with NMG, reached at the end of the study a BP of Ͻ140/90 mm Hg. The outpatient control of BP with the use of a mercury sphygmomanometer shows a significant decrease after 3 weeks of treatment, maintaining its stability after 12 weeks, without differences in the response between study groups. Reduction in BP reduces the cardiovascular morbimortality. The INSIGHT 13 study was designed for this purpose and revealed a reduction of events of 50% under treatment with osmotic pump nifedipine, when compared with the treatment of diuretics (hydrochlorothiazide and amiloride). On the other hand, a meta-analysis with randomised studies, doubleblind with antihypertensive agents and its action in the regression of the ventricular hypertrophy, the calcium antagonists are in second place with 9%, after the IECA, with 13% before diuretics 7% and beta-blockers 6%. 14 Ventricular hypertrophy is an independent risk factor for coronary heart disease, cardiac insufficiency and fatal arrhythmias. 15 The HOT study cleared doubts about the intensity of the decrease in BP using felodipine, another calcium antagonist; decrease of BP below 80 mm Hg was associated with lower number of events and deaths of cardiovascular origin. 16 Heart rate in this study shows a slight increase under treatment with NOP and a slight decrease with NMG. This fact is due to the changes of nifedipine with controlled release formulations and the development of agents with long biological half lives. 17 These results with NOP were similar in other studies in which there was an increase of the HR and of the double product in the morning hours. 18 The therapeutic efficacy of the osmotic pump nifedipine has been fully established. 5, 6 In this study, it is compared with nifedipine with another form of release by microgranules which enables a slow release, used as monotherapy for high blood pressure and stable effect for 24 h, with the same dose once a day, for which ABPM is used with the calculation and measurement of MAP in 24 h, minimising the variability of BP when comparing both formulations. 19 By fulfilling the primary object of this design and leaving for subsequent assessments other considerations such as circadian behaviour, trough-peak ratio, 'uniformity index' and double product, we can confirm as a main result equal considerations of therapeutic effect as that achieved with the taking of BP with a sphygmomanometer, also a similar and significant decrease in BP from the third week. Beginning with a similar basal level of BP, both formulations reduce BP without significant differences after the third week within a context of good tolerance and few side effects.
